Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
COAG
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. (COAG) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.1
/ 5.0
C-
Value
C+
Factor Score
2.5
/ 5.0
Growth
C-
Factor Score
2.1
/ 5.0
Profitability
D-
Factor Score
0.8
/ 5.0
Momentum
C
Factor Score
2.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-15.2
EV / EBITDA
-17.8
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-27.5%
Price Return 12M
14.0%
Catalyst Signal
0.00
Market Cap
$1.8B
TTM Revenue
N/A
Price / Sales
N/A
ROE
N/A
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C- (2.1) | D- (0.8) | C (2.5) | C+ (2.6) | C- (2.1) |
| 2026-11-04 | C+ (2.5) | C- (2.1) | D- (0.8) | C+ (2.7) | C+ (2.7) | C (2.2) |
| 2026-10-28 | C+ (2.5) | C- (2.1) | D- (0.8) | C (2.3) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | C+ (2.5) | C- (2.1) | D- (0.8) | C (2.3) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | C+ (2.5) | C- (2.1) | D- (0.8) | C+ (2.5) | C+ (2.6) | C- (2.1) |
Page
1
of
4